NDA 021852 · Leo Pharma As
Taclonex
Betamethasone Dipropionate, Calcipotriene · Topical
Last checked: Nov 20, 2026Latest source record: Dec 21, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Jan 9, 2006
Approved uses
2
Original approval plus efficacy supplements
Registered trials
127
30 Phase 3, 11 recruiting
FAERS reports
1,723
791 serious, 37 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 12, 2022.
Calcipotriene and Betamethasone Dipropionate Ointment is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. Calcipotriene and Betamethasone Dipropionate Ointment is a vitamin D analogue and corticosteroid combination product indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. ( 1 )
Mechanism: Calcipotriene and Betamethasone Dipropionate Ointment combines the pharmacological effects of calcipotriene hydrate as a synthetic vitamin D 3 analogue and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in plaque psoriasis are unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 23, 2014 Supplement 15 · Efficacy Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewLetter
- Jan 9, 2006 Original approval · Type 4 - New Combination LabelReviewLetter
1 products under this application
- TACLONEX · BETAMETHASONE DIPROPIONATE 0.064%; CALCIPOTRIENE 0.005% · OINTMENT, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Betamethasone Dipropionate" as an intervention, any sponsor and status, largest first.
- Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)Pivotal-lookingRecruiting
McMaster UniversityAcademic, hospital or other
NCT05114096 · 3,254 participants (planned) · Start Jul 20, 2023 · Primary completion Dec 31, 2026
Drug: Celestone + placebo; Celestone + Celestone · For: Preterm Birth; Premature Birth; Complication of Prematurity and 2 more
Sites: Calgary, Canada; Edmonton, Canada; New Westminster, Canada · 25 sites in all
- Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp PsoriasisPivotal-lookingCompleted
LEO PharmaIndustry
NCT00216827 · 1,485 participants · Start Nov 2004
Drug: Calcipotriol plus betamethasone dipropionate (LEO80185 gel) · For: Psoriasis of Scalp
Sites: Québec, Canada; Roskilde, Denmark; Nice, France · 8 sites in all
- Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp PsoriasisPivotal-lookingCompleted
LEO PharmaIndustry
NCT00216840 · 1,350 participants · Start Dec 2004
Drug: Calcipotriol plus betamethasone dipropionate (LEO80185 gel) · For: Psoriasis of Scalp
Sites: Leuven, Belgium; Montreal, Canada; Turku, Finland · 7 sites in all
- LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)Pivotal-lookingCompleted
LEO PharmaIndustry
NCT01188928 · 1,152 participants · Start Sep 2010 · Primary completion Mar 2011
Drug: Calcipotriol plus betamethasone; Betamethasone-17,21-dipropionate and 2 more · For: Psoriasis Vulgaris
Sites: Mobile, Alabama; Hot Springs, Arkansas; Anaheim, California · 59 sites in all
- Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis VulgarisPivotal-lookingCompleted
LEO PharmaIndustry
NCT00216892 · 1,032 participants · Start Apr 2005
Drug: Calcipotriol, (calcipotriol + betamethasone) · For: Psoriasis Vulgaris
Sites: Ghent, Belgium; Hamilton, Canada; Saint-Etienne, France · 7 sites in all
- Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp PsoriasisPivotal-lookingCompleted
LEO PharmaIndustry
NCT00216879 · 800 participants · Start Feb 2005
Drug: Calcipotriol plus betamethasone dipropionate gel (LEO 80185) · For: Psoriasis of Scalp
Sites: Moncton, Canada; Hørsholm, Denmark; Saint-Etienne, France · 5 sites in all
- A Clinical Trial Evaluating Efficacy and Safety of MC2-01 CreamPivotal-lookingCompleted
MC2 TherapeuticsIndustry
NCT03308799 · 794 participants · Start Oct 3, 2017 · Primary completion Jun 8, 2018
Drug: MC2-01 cream; Cal/BDP combination and 1 more · For: Psoriasis Vulgaris
Sites: Detroit, Michigan; Fridley, Minnesota; Spokane, Washington
- Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic TreatmentPivotal-lookingCompleted
AbbottIndustry
NCT00574249 · 730 participants · Start Nov 2007 · Primary completion Oct 2008
Drug: adalimumab; Calcipotriol/Betamethasone Ointment and 1 more · For: Chronic Plaque Psoriasis
Sites: Graz, Austria; Innsbruck, Austria; Salzburg, Austria · 131 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- psoriasis365
- drug ineffective188
- diarrhoea122
- headache114
- nausea114
- pruritus100
- arthralgia81
- fatigue80
- rash80
- pain79
- injection site pain60
- erythema57
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 12 |
| 2008 | 30 |
| 2009 | 29 |
| 2010 | 44 |
| 2011 | 62 |
| 2012 | 123 |
| 2013 | 114 |
| 2014 | 97 |
| 2015 | 203 |
| 2016 | 183 |
| 2017 | 154 |
| 2018 | 139 |
| 2019 | 124 |
| 2020 | 100 |
| 2021 | 58 |
| 2022 | 63 |
| 2023 | 90 |
| 2024 | 46 |
| 2025 | 36 |
| 2026 | 14 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Taclonex (Calcipotriene/Betamethasone)
2024 spending
$410K
Beneficiaries
81
202 claims
Per beneficiary
$5,057
$21.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,216,475 |
| 2021 | $1,105,654 |
| 2022 | $651,830 |
| 2023 | $664,968 |
| 2024 | $409,582 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Management of Residual Psoriasis in Patients on Biologic Treatment.
Haidari W, Pona A, Feldman SR · J Drugs Dermatol 2020 · Systematic Review
- Proactive Topical Maintenance Treatment of Psoriasis: Subanalysis of Canadian Patients in the Phase III PSO-LONG Trial.
Hong HC, Adam DN, Rivers JK, et al. · J Cutan Med Surg 2023 · Clinical Trial, Phase III, Letter
- Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review.
Yan R, Jiang S, Wu Y, et al. · Indian J Dermatol Venereol Leprol 2016 · Research Support, Non-U.S. Gov't, Systematic Review
- Treatments for Cutaneous Lichen Planus: A Systematic Review and Meta-Analysis.
Atzmony L, Reiter O, Hodak E, et al. · Am J Clin Dermatol 2016 · Meta-Analysis, Systematic Review
- The Effect on BSA of Proactive Management versus Reactive Management of Psoriasis With Fixed-Dose Cal/BD Foam in the PSO-LONG Study.
Takhar A, Thoning H, Nyholm N, et al. · J Drugs Dermatol 2021 · Randomized Controlled Trial
- Interventions for hand eczema.
Christoffers WA, Coenraads PJ, Svensson Å, et al. · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Leo Pharma As
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.